Back to Search Start Over

Evaluation of σ-1 receptor radioligand 18F-FTC-146 in rats and squirrel monkeys using PET.

Authors :
James ML
Shen B
Nielsen CH
Behera D
Buckmaster CL
Mesangeau C
Zavaleta C
Vuppala PK
Jamalapuram S
Avery BA
Lyons DM
McCurdy CR
Biswal S
Gambhir SS
Chin FT
Source :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2014 Jan; Vol. 55 (1), pp. 147-53. Date of Electronic Publication: 2013 Dec 12.
Publication Year :
2014

Abstract

Unlabelled: The noninvasive imaging of σ-1 receptors (S1Rs) could provide insight into their role in different diseases and lead to novel diagnostic/treatment strategies. The main objective of this study was to assess the S1R radiotracer (18)F-FTC-146 in rats. Preliminary squirrel monkey imaging and human serum/liver microsome studies were performed to gain information about the potential of (18)F-FTC-146 for eventual clinical translation.<br />Methods: The distribution and stability of (18)F-FTC-146 in rats were assessed via PET/CT, autoradiography, γ counting, and high-performance liquid chromatography (HPLC). Preliminary PET/MRI of squirrel monkey brain was conducted along with HPLC assessment of (18)F-FTC-146 stability in monkey plasma and human serum.<br />Results: Biodistribution studies showed that (18)F-FTC-146 accumulated in S1R-rich rat organs, including the lungs, pancreas, spleen, and brain. Pretreatment with known S1R compounds, haloperidol, or BD1047, before radioligand administration, significantly attenuated (18)F-FTC-146 accumulation in all rat brain regions by approximately 85% (P < 0.001), suggesting radiotracer specificity for S1Rs. Similarly, PET/CT and autoradiography results demonstrated accumulation of (18)F-FTC-146 in rat brain regions known to contain S1Rs and that this uptake could be blocked by BD1047 pretreatment. Ex vivo analysis of (18)F-FTC-146 in the brain showed that only intact radiotracer was present at 15, 30, and 60 min, whereas rapid metabolism of residual (18)F-FTC-146 was observed in rat plasma. Preliminary monkey PET/MRI studies demonstrated specific accumulation of (18)F-FTC-146 in the brain (mainly in cortical structures, cerebellum, and vermis) that could be attenuated by pretreatment with haloperidol. HPLC of monkey plasma suggested radioligand metabolism, whereas (18)F-FTC-146 appeared to be stable in human serum. Finally, liver microsome studies revealed that (18)F-FTC-146 has a longer half-life in human microsomes, compared with rodents.<br />Conclusion: Together, these results indicate that (18)F-FTC-146 is a promising tool for visualizing S1Rs in preclinical studies and that it has potential for mapping these sites in the human brain.

Details

Language :
English
ISSN :
1535-5667
Volume :
55
Issue :
1
Database :
MEDLINE
Journal :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Publication Type :
Academic Journal
Accession number :
24337599
Full Text :
https://doi.org/10.2967/jnumed.113.120261